Arca
Skip to content
Tools
Tools

Biliary cancer

Drug research and approvals for biliary cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 227 studies of biliary cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 12 drug trials for it since 2013.

  • Recruiting worldwide: 227
  • Trials authorized in Canada: 12
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 227 recruiting on ClinicalTrials.gov ↗

How its trials ended

383 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 83 whose ending is known, 37% met their primary endpoint, 11% missed it and 52% stopped early.

  • Ongoing15841%
  • Completed, result not reported7820%
  • Status unknown6417%
  • Met its primary endpoint318%
  • Stopped: other or unclear195%
  • Missed its primary endpoint92%
  • Stopped: lack of efficacy92%
  • Stopped: enrollment or feasibility92%
  • Stopped: sponsor or business decision51%
  • Stopped: funding1<1%

Trials authorized in Canada

The 10 newest of 12; search them all in Canada trials
Oct 29, 2026A phase 2, open-label, master protocol study to evaluate safety and efficacy of treatment combinations with telisotuzumab adizutecan in subjects with…Telisotuzumab adizutecan (ABBV-400) / GemcitabineAbbViePending
Oct 22, 2025Phase III, randomized, open-label, global, multicenter study of rilvegostomig or durvalumab in combination with chemotherapy as a first-line treatment for…Imfinzi / RilvegostomigAstraZeneca PharmaceuticalsOngoing
May 30, 2024Beamion pantumor-1: a phase II, multicentre, multicohort, open label trial to evaluate the efficacy and safety of oral zongertinib (bi 1810631) for the…Zongertinib (bi 1810631)Boehringer Ingelheim (Canada) Ltd LteeOngoing
Mar 26, 2024A phase 1b study evaluating the safety, tolerability, pharmacokinetics, and efficacy of amg 193 in combination with other therapies in subjects with advanced…Amg 193AmgenPending
Jul 7, 2021A first in human, open label, dose escalation phase I study evaluating the safety, pharmacokinetics, and preliminary clinical activity profile of single agent…RO7119929 / Tocilizumab (RO4877533)RochePending
Dec 8, 2020A phase II randomized, double-blind placebo-controlled study of atezolizumab with or without bevacizumab in combination with cisplatin plus gemcitabine in…Tecentriq / AvastinRocheClosed
Aug 21, 2019"a phase 3 randomized, double blind study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in…Keytruda (MK-3475) / Cisplatin / GemcitabineMerck & Co. (MSD)Ongoing
May 23, 2019Phase III open-label, multi-centre, randomised study comparing NUC-1031 plus cisplatin to gemcitabine plus cisplatin in patients with previously untreated…Fosgemcitabine palabenamide (NUC-1031)/ Gemcitabine/ CisplatinNuCanaClosed
Nov 3, 2015A multicentre, open-label phase II study of nab-paclitaxel in combination with gemcitabine + cisplatin as first line treatment in patients with unresectable…Paclitaxel/ Gemcitabine/ CisplatinCross Cancer Institute - Cancer Care AlbertaOngoing
Jun 27, 2014A randomized phase II trial of mek inhibitor selumetinib (AZD6244) combined continuously or sequentially with cisplatin/gemcitabine (cis/gem) versus cis/gem…Selumetinib/ Cisplatin/ GemcitabinePrincess Margaret Cancer CentreClosed

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.